Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin-c + cisplatin
- Development stage
- Unknown
- Lead developer
- Kyowa Kirin
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Mitomycin-c + cisplatin is a combination chemotherapy regimen consisting of two antineoplastic agents—mitomycin-C and cisplatin. Mitomycin-C is an alkylating agent that cross-links DNA, inhibiting DNA synthesis and leading to cell death. Cisplatin is a platinum-based chemotherapeutic that forms DNA adducts and cross-links, also disrupting DNA replication and transcription. This combination has demonstrated antitumor activity in several malignancies, including advanced or recurrent squamous-cell carcinoma of the uterine cervix[1], malignant mesothelioma[2], and has been studied in other solid tumors such as non-small cell lung cancer (NSCLC)[5]. The regimen is generally administered intravenously on a cyclical basis and can be given on an outpatient basis. Toxicities are primarily gastrointestinal and hematological but are considered manageable.
- Brand names
- PlatinolJelmytoMitosolMutamycin
- Other names
- mitomycin C + cisplatinmitomycin + cisplatinMMC + cisplatin
02
Targets
DNA
Beyond the preview
Go deeper on mitomycin-c + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin-c + cisplatin.